News

Quotient Sciences Celebrates Grand Opening of New Alnwick Drug Substance Facility With Official Ribbon Cutting

Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting at our Alnwick facility.

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03.

Oxilio announces start of its first clinical trial with OXL001

Oxilio has commenced first human subject dosing of OXL001. The product leverages the Quotient Sciences Translational Pharmaceutics® platform for drug development.

Emplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient Sciences

Emplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.

Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility

Quotient Sciences, the drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility in Alnwick, UK. The £6 million project results in a state-of-the-art drug substance manufacturing capability that can deliver integrated support for customers from candidate selection through to early clinical development and beyond.

Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

Oxilio and Quotient Sciences announced an update on the development of Oxilio’s OXL001 product, which uses Quotient Sciences’ Translational Pharmaceutics® platform.